NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression | Psychiatric Times
· psychiatrictimes.com · popularity 16/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at psychiatrictimes.com →
Summary
Data Supporting COMP360 The NDA submission is supported by data from Compass’ 2 positive phase 3 clinical trials, COMP005 and COMP006, which involved …
Found in: Mental Health. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 19.